Revenue recovered to $7.5M in 2026Q3 with gross margin of 7.4%, but operating margin of -166.9% and a net loss of $11.1M indicate that unit economics and R&D intensity still prevent operating leverage at current scale.
Hyliion Holdings Corp. (HYLN) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 15.94M | 3.48M | 1.51M | 672K | 2.11M | 200K | 0 | 0 | 0 |
| Revenue Growth % | 273.13% | 130.28% | 124.55% | -68.09% | 953% | - | - | - | - |
| Cost of Goods Sold | 18.74M | 9.26M | 1.42M | 1.72M | 8.78M | 2.74M | 1.78M | 2.34M | 0 |
| COGS % of Revenue | - | 266.5% | 93.77% | 255.36% | 416.81% | 1368.5% | - | - | - |
| Gross Profit | -2.8M | -5.79M | 94K | -1.04M | -6.67M | -2.54M | -1.78M | -2.34M | 0 |
| Gross Margin % | -17.55% | -166.5% | 6.23% | -155.36% | -316.81% | -1268.5% | - | - | - |
| Gross Profit Growth % | - | -6255.32% | 109% | 84.35% | -162.99% | -42.69% | 24.02% | - | - |
| Operating Expenses | 54M | 59.27M | 64.39M | 136.32M | 152.36M | 93.56M | 20.41M | 9.66M | 19.86M |
| OpEx % of Revenue | - | 1705.55% | 4267.26% | 20286.46% | 7234.47% | 46780% | - | - | - |
| Selling, General & Admin | 18.43M | 22.3M | 24.38M | 42.61M | 41.99M | 35.3M | 8.46M | 1.22M | 4.07M |
| SG&A % of Revenue | - | 641.76% | 1615.77% | 6340.92% | 1993.73% | 17649.5% | - | - | - |
| Research & Development | 35.83M | 36.97M | 1.51M | 82.24M | 110.37M | 58.26M | 11.95M | 8.44M | 15.73M |
| R&D % of Revenue | - | 1063.8% | 100% | 12238.1% | 5240.74% | 29130.5% | - | - | - |
| Other Operating Expenses | -258K | 0 | 38.5M | 11.47M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56.8M | -65.05M | -64.3M | -137.37M | -159.03M | -96.1M | -22.18M | -12M | -19.86M |
| Operating Margin % | -356.31% | -1872.06% | -4261.03% | -20441.82% | -7551.28% | -48048.5% | - | - | - |
| Operating Income Growth % | - | -1.17% | 53.19% | 13.62% | -65.49% | -333.2% | -84.87% | 39.57% | - |
| EBITDA | -48.88M | -59.1M | -61.15M | -133.86M | -157.8M | -95.21M | -21.33M | -10.97M | -19.07M |
| EBITDA Margin % | -306.64% | -1700.66% | -4052.49% | -19919.35% | -7493.02% | -47606.5% | - | - | - |
| EBITDA Growth % | 20.75% | 3.36% | 54.32% | 15.17% | -65.74% | -346.32% | -94.45% | 42.48% | - |
| D&A (Non-Cash Add-back) | 7.92M | 5.96M | 3.15M | 3.51M | 1.23M | 884K | 850K | 1.03M | 780K |
| EBIT | -49.91M | -57.19M | -61.29M | -125.89M | -153.36M | -96.05M | 329.58M | -10.85M | -591 |
| Net Interest Income | 5.95M | 8.35M | 12.22M | 13.81M | 5.72M | 779K | 0 | 0 | 0 |
| Interest Income | 5.95M | 8.35M | 12.22M | 13.81M | 5.72M | 779K | 5.46M | 3.26M | 366K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 5.46M | 3.26M | 0 |
| Other Income/Expense | 6.88M | 7.87M | 12.25M | 13.86M | 5.67M | 49K | 346.3M | -2.11M | 574K |
| Pretax Income | -49.91M | -57.19M | -52.05M | -123.51M | -153.36M | -96.05M | 324.12M | -14.11M | -19.28M |
| Pretax Margin % | -313.12% | -1645.7% | -3449.17% | -18379.46% | -7281.91% | -48024% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19.8M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 102.7% |
| Net Income | -49.91M | -57.19M | -52.05M | -123.51M | -153.36M | -96.05M | 324.12M | -14.11M | -591 |
| Net Margin % | -313.12% | -1645.7% | -3449.17% | -18379.46% | -7281.91% | -48024% | - | - | - |
| Net Income Growth % | 14.54% | -9.88% | 57.86% | 19.46% | -59.67% | -129.63% | 2396.58% | - | - |
| Net Income (Continuing) | -49.91M | -57.19M | -52.05M | -123.51M | -153.36M | -96.05M | 324.12M | -14.11M | -591 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28 | -0.33 | -0.30 | -0.68 | -0.87 | -0.56 | 0.00 | -0.20 | 0.00 |
| EPS Growth % | 15.76% | -10% | 55.88% | 21.84% | -55.36% | - | 100% | - | - |
| EPS (Basic) | - | -0.33 | -0.30 | -0.68 | -0.87 | -0.56 | 3.11 | -0.20 | 0.00 |
| Diluted Shares Outstanding | 178.72M | 175.43M | 174.91M | 181.41M | 175.4M | 172.22M | 104.32B | 86.64M | 28.13M |
| Basic Shares Outstanding | 178.72M | 175.43M | 174.91M | 181.41M | 175.4M | 172.22M | 104.32M | 86.64M | 28.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying HYLN stock.
For fiscal year 2025, Hyliion Holdings Corp. (HYLN) reported total revenue of $3.5M.
Hyliion Holdings Corp. (HYLN) reported a net loss of $57.2M for the fiscal year ending 2025.
Hyliion Holdings Corp. (HYLN) reported an operating income of $-65.1M, resulting in an operating profit margin of -1872.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Hyliion Holdings Corp. (HYLN) generated $-5.8M in gross profit for the year, representing a gross profit margin of -166.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses and funding dependence
Metrics are mathematically derived from official filings.
Revenue Rebound From Near-Zero Base
Based on reported quarterly figures, HYLN's revenue rose from $712.0K in 2025Q4 to $7.5M in 2026Q3, a step-up that appears significant but rests on a very small and volatile base that may not yet indicate durable growth. Investors should monitor whether this rebound persists across subsequent quarters.
The quarterly series shows revenue fluctuating sharply, with no clear compounding pattern, which suggests growth is driven by lumpy project or pilot deliveries rather than recurring demand. The reported 8.8% sequential-style revenue growth figure in the latest quarter is difficult to interpret in isolation given the earlier collapse to sub-$1M levels. Forward guidance of roughly $3M sitting well below the latest quarter further suggests the recent spike may be non-recurring, warranting caution before extrapolating it.
Negative Gross Margin Signals Unit Economics Gap
Gross margin has remained negative for most of the reported history, reaching -67.1% in 2026Q1 and only briefly turning positive at 7.4% in 2026Q2 and 2026Q3, suggesting that unit costs have not yet been consistently covered by revenue.
The thin positive gross margins in the two most recent quarters, while encouraging, are small in absolute dollars and do not yet establish a repeatable cost structure. Given that COGS of $6.9M in the latest quarter nearly equals revenue, the margin appears highly sensitive to small changes in volume or input costs. Until gross profit stabilizes over multiple periods, the margin profile should be treated as unproven rather than structurally improved.
Operating Losses Dwarf Gross Profit
Operating expenses, led by R&D of $8.7M and SG&A of $4.3M in 2026Q3, far exceed gross profit of $552.0K, producing an operating loss of $12.4M that implies minimal operating leverage at current scale.
With operating margin reported at -166.9% in the latest quarter, revenue has not yet grown fast enough to absorb the fixed cost base. The R&D line remains the dominant expense, which is consistent with a company still engineering its core technology rather than operating a scaled production business. Operating leverage would only become meaningful if revenue expands by a multiple while R&D spending plateaus.
Net Loss Tracks Operating Loss Closely
Reported net loss of $11.1M in 2026Q3 is smaller than the $12.4M operating loss, and EPS of -$0.06 was reported, though the quarter's EPS estimate comparison remains unverified in the supplied data.
The modest gap between operating and net loss suggests few large non-operating items distorted the quarter, which supports a more direct reading of underlying performance. Stock-based compensation of $1.6M is a non-trivial portion of the expense base and may flatter cash-based comparisons relative to earnings. The unreported EPS versus estimate status limits any conclusion about whether results met market expectations.
R&D Intensity Defines the Cost Base
R&D expense of $8.7M in 2026Q3 and $9.5M in 2026Q2 represents the largest single cost line, indicating that development spending rather than production overhead is the primary driver of reported losses.
R&D has remained in a range of roughly $7.7M to $12.2M across the reported quarters, showing little evidence of meaningful expense discipline despite revenue recovery. Because the company's commercial case depends on converting development work into saleable product, this spending pattern suggests continued capital need. Investors should watch whether R&D begins to decline as a share of revenue as commercial volumes build.
Revenue Spike May Prove Non-Recurring
The sharp rise to $7.5M in the latest quarter, set against forward guidance of about $3M, raises the possibility that the rebound is a one-off delivery rather than a sustainable run rate, a risk the reported figures cannot resolve on their own.
Reading the quarterly data at face value, the gap between the most recent quarter and guidance suggests management itself may not expect the level to hold, which weakens the growth narrative. Negative gross margins for most of the period imply that even the higher revenue quarters did not reliably cover direct costs. Without cash flow and balance sheet detail for the latest quarter, the sustainability of the funding base supporting these losses remains an open question warranting further investigation.